Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$70.57 USD
+0.20 (0.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $70.64 +0.07 (0.10%) 5:36 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 501 - 520 ( 714 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
CHMP Recommends Promacta for SAA; Nearing Kyprolis'' sNDA PDUFA for MM
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Promacta Approved for Pediatric cITP, the First Under Novartis
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Teeing Up Next Partnering Event; ''6972 Shines at ADA
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
CVR Cash In; Tweaking Model and Upping Target to $135
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
"Low Hanging Fruit" Promacta Data for Next Potential Growth Phase
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
SAGE Going Pivotal Off of Positive Phase I/II; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
1Q15 Results, Pipeline Expands and Partners Cranking; Target to $127
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J